(Q33383951)

26 July 2017

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation (English)

1 reference

26 July 2017

4

Antonello Vidiri

1 reference

26 July 2017

Carmine Maria Carapella

Carmine Maria Carapella

5

0 references

Marta Maschio

Marta Maschio

6

0 references

Isabella Sperduti

Isabella Sperduti

10

0 references

Giulio Metro

2

Giulio Metro

1 reference

26 July 2017

Alessandra Fabi

1

1 reference

26 July 2017

Michelangelo Russillo

3

1 reference

26 July 2017

Francesco Cognetti

7

1 reference

26 July 2017

Bruno Jandolo

8

1 reference

26 July 2017

Maria Alessandra Mirri

9

1 reference

26 July 2017

Stefano Telera

11

1 reference

26 July 2017

Mariantonia Carosi

12

1 reference

26 July 2017

Andrea Pace

13

1 reference

26 July 2017

language of work or name

English

0 references

publication date

31 March 2009

1 reference

26 July 2017

1 reference

26 July 2017

9

1 reference

26 July 2017

101

1 reference

Creative Commons Attribution 2.0 Generic

26 July 2017

start time

31 March 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2407-9-101

0 references

cites work

Malignant gliomas in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

MGMT gene silencing and benefit from temozolomide in glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

PCV chemotherapy for recurrent glioblastoma multiforme.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

Phase II study of fotemustine in recurrent supratentorial malignant gliomas

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2667532

Recent clinical trials and future therapies

14 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-101

Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-101

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-101

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-101

BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-101

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-101

Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-101

Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-101

Antitumor activity of the novel nitrosourea S10036 in rodent tumors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19335893

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19335893

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2407-9-101

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference